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MYC contributes to the pathogenesis of a majority of
human cancers, yet strategies to modulate the func-
tion of the c-Myc oncoprotein do not exist. Toward
this objective, we have targeted MYC transcription
by interferingwith chromatin-dependent signal trans-
duction to RNA polymerase, specifically by inhibiting
the acetyl-lysine recognition domains (bromodo-
mains) of putative coactivator proteins implicated in
transcriptional initiation and elongation. Using a se-
lective small-molecule bromodomain inhibitor, JQ1,
we identify BET bromodomain proteins as regulatory
factors for c-Myc. BET inhibition by JQ1 downregu-
lates MYC transcription, followed by genome-wide
downregulation of Myc-dependent target genes. In
experimental models of multiple myeloma, a Myc-
dependent hematologic malignancy, JQ1 produces
a potent antiproliferative effect associated with cell-
cycle arrest and cellular senescence. Efficacy of
JQ1 in three murine models of multiple myeloma
establishes the therapeutic rationale for BET bromo-
domain inhibition in this disease and other malignan-
cies characterized by pathologic activation of c-Myc.
INTRODUCTION
c-Myc is a master regulatory factor of cell proliferation (Dang
et al., 2009). In cancer, pathologic activation of c-Myc plays
a central role in disease pathogenesis by the coordinated upre-
gulation of a transcriptional program influencing cell division,
metabolic adaptation, and survival (Dang, 2009; Kim et al.,904 Cell 146, 904–917, September 16, 2011 ª2011 Elsevier Inc.2008). Amplification ofMYC is among the most common genetic
alterations observed in cancer genomes (Beroukhim et al.,
2010). Validation of c-Myc as a therapeutic target is supported
by numerous lines of experimental evidence. Murine models of
diverse malignancies have been devised by introducing genetic
constructs overexpressingMYC (Harris et al., 1988; Leder et al.,
1986; Stewart et al., 1984). In addition, conditional transgenic
models featuring tunable transcriptional suppression have
shown that even transient inactivation ofMYC is capable of pro-
moting tumor regression (Jain et al., 2002; Soucek et al., 1998;
Soucek et al., 2002). Elegant studies of systemic induction of
a dominant-negative MYC allele within an aggressive, KRAS-
dependent murine model of lung adenocarcinoma have further
suggested the putative therapeutic benefit of c-Myc inhibition
(Fukazawa et al., 2010). Importantly, these studies establish
the feasibility of c-Myc inhibition within an acceptable thera-
peutic window of tolerability.
Nevertheless, a therapeutic approach to target c-Myc has re-
mained elusive. The absence of a clear ligand-binding domain
establishes a formidable obstacle toward direct inhibition, which
is a challenging feature shared among many compelling tran-
scriptional targets in cancer (Darnell, 2002). c-Myc functions as
a DNA-binding transcriptional activator upon heterodimerization
with another basic-helix-loop-helix leucine zipper (bHLH-LZ)
transcription factor, Max (Amati et al., 1993; Blackwood and
Eisenman, 1991). High-resolution structures of the complex fail
to identify a hydrophobic involution compatible with the posi-
tioning of an organic small molecule (Nair and Burley, 2003).
Therefore, we have targeted c-Myc transcriptional function by
another means, namely the disruption of chromatin-dependent
signal transduction (Schreiber and Bernstein, 2002). c-Myc tran-
scription is associated locally and globally with increases in
histone lysine side-chain acetylation, a covalent modification of
chromatin that is regionally associated with transcriptional
activation (Frank et al., 2003; Vervoorts et al., 2003). Histone
acetylation templates the assembly of higher-ordered transcrip-
tional complexes by recruiting proteins with one or more acetyl-
lysine-binding modules or bromodomains (Dhalluin et al., 1999;
Haynes et al., 1992). Members of the bromodomain and extrater-
minal (BET) subfamily of human bromodomain proteins (BRD2,
BRD3, and BRD4) associate with acetylated chromatin and facil-
itate transcriptional activation by increasing the effective mo-
larity of recruited transcriptional activators (Rahman et al.,
2011). Notably, BRD4 has been shown to mark select M/G1
genes in mitotic chromatin as transcriptional memory and direct
postmitotic transcription (Dey et al., 2009) via direct interaction
with the positive transcription elongation factor complex
b (P-TEFb) (Bisgrove et al., 2007). The discovery that c-Myc
regulates promoter-proximal pause release of Pol II, also
through the recruitment of P-TEFb (Rahl et al., 2010), established
a rationale for targeting BET bromodomains to inhibit c-Myc-
dependent transcription.
Recently, we reported the development and biochemical char-
acterization of a potent, selective small-molecule inhibitor of BET
bromodomains, JQ1 (Figure 1A) (Filippakopoulos et al., 2010).
JQ1 is a thieno-triazolo-1,4-diazepine that displaces BET
bromodomains from chromatin by competitively binding to the
acetyl-lysine recognition pocket. In the present study, we
leverage the properties of JQ1 as a chemical probe (Frye,
2010) to interrogate the role of BET bromodomains in Myc-
dependent transcription and to explore the role of BET bromo-
domains as cancer dependencies.
Multiple myeloma (MM) represents an ideal model system for
these mechanistic and translational questions, given the known
role of MYC in disease pathophysiology. MM is an incurable
hematologic malignancy that is typified by the accumulation of
malignant plasma cells harboring diverse genetic lesions
(Chapman et al., 2011). Dysregulation of transcription factors
features prominently in the biology of MM, including NF-kB
(Keats et al., 2007), c-Maf (Hurt et al., 2004), XBP1 (Claudio
et al., 2002), HSF1 (Mitsiades et al., 2002), GR (Gomi et al.,
1990), IRF4 (Shaffer et al., 2008), Myb (Palumbo et al., 1989),
and, notably, c-Myc (Dean et al., 1983). Rearrangement or trans-
location ofMYC are among the most common somatic events in
early- and late-stage MM (Shou et al., 2000), and transcriptional
profiling identifies Myc pathway activation in more than 60% of
patient-derived MM cells (Chng et al., 2011). Experimental
support for the central role of c-Myc in the pathogenesis of
MM is contributed by an informative, genetically engineered
murine model of MM. Lineage-specific and stochastic activa-
tion-induced deaminase (AID)-dependent activation of a condi-
tional MYC transgene in the late stages of B cell differentiation
establishes genetically engineered mice with a plasma cell
malignancy that shares clinically relevant features of MM (Chesi
et al., 2008). Thus, MYC dysregulation represents a largely uni-
fying molecular feature observed across the otherwise complex
genetic landscape of MM.
In this study, we report that c-Myc transcriptional function can
be modulated pharmacologically by BET bromodomain inhibi-
tion. Unexpectedly, we have discovered that MYC itself is tran-
scriptionally regulated by BET bromodomains. Chromatin immu-
noprecipitation studies show that BRD4 is strongly enrichedat immunoglobulin heavy-chain (IgH) enhancers in MM cells
bearing IgH rearrangement at the MYC locus. BET inhibition
with JQ1 depletes enhancer-bound BRD4 and promptly inhibits
MYC transcription in a dose- and time-dependent manner. In
translational models of MM, JQ1 leads to depletion of the
c-Myc oncoprotein and selective downregulation of the coordi-
nated c-Myc transcriptional program, prompting cell-cycle
arrest and cellular senescence. These results indicate that
targeting protein-protein interactions within the c-Myc transcrip-
tional signaling network can modulate the function of c-Myc in
cancer.RESULTS
BET Bromodomains as Therapeutic Targets in MM
We first evaluated the expression of BRD2, BRD3, BRD4, and
BRDT transcripts in MM by integrating publicly available com-
pendia of gene expression data sets. Among asymptomatic
patients with premalignant disease (Zhan et al., 2007), we
observed increasing expression ofBRD4 in monoclonal gammo-
pathy of undetermined significance (MGUS) and smoldering
MM (SMM) compared to normal bone marrow plasma cells (Fig-
ure 1B). In a second, independent data set (Mattioli et al., 2005),
we observed significantly higher expression of BRD4 in plasma
cell leukemia (PCL) compared to MM or MGUS samples (Fig-
ure 1C). Thus, BRD4 expression correlates positively with
disease progression. BRD2 and BRD3 are also expressed in
MM, but expression does not clearly correlate with stage of
disease (data not shown). BRDT, a testis-specific bromodo-
main-containing protein, is not expressed in MM.
Analysis of copy number polymorphism (CNP) data collected
on 254 MM patients by the Multiple Myeloma Research Consor-
tium (MMRC) revealed that the BRD4 locus is frequently ampli-
fied in MM patient samples (Figure 1D). The majority of patient
samples exhibit broad amplification of chromosome 19p, but
focal amplification at the BRD4 locus is observed (Figure S1
available online). Among 45 established MM cell lines, expres-
sion of BRD4 was pronounced and did not correlate with ampli-
fication status (Figure 1E).
HumanMM cells are highly osteotropic in vivo, and interaction
with bone marrow stromal cells (BMSCs) induces proliferation
and contributes to drug resistance (McMillin et al., 2010). Ana-
lysis of BET bromodomain expression, as influenced by MM
cell binding to BMSCs (McMillin et al., 2010), revealed marked
upregulation of BRD4 in the INA-6 human MM cell line upon
interaction with HS5 stromal cells (Figure 1F), suggesting a plau-
sible role for BRD4 function in MM cells within the bone marrow
microenvironment.
To explore the function of BET bromodomains in MM, we
examined the effect on proliferation of small hairpin RNAs
(shRNAs) targeting each of the four BET proteins in comparison
to shRNAs targeting 1011 kinases, phosphatases, and onco-
genes in a lentivirally delivered, arrayed shRNA screen in INA-6
cells. As illustrated in Figures 1G and 1H, shRNA constructs
targeting each of the expressed BET bromodomains are identi-
fied as reducing INA-6 proliferation as shown by normalized
B scores (Malo et al., 2006). Together, these data establishCell 146, 904–917, September 16, 2011 ª2011 Elsevier Inc. 905
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Figure 1. Integrated Genomic Rationale for BET Bromodomains as Therapeutic Targets in MM
(A) Structures of the BET bromodomain inhibitors JQ1 and iBET.
(B and C) Expression levels (log2 transformed, median-centered values) for BRD4 transcripts were evaluated in oligonucleotide microarray data from normal
plasma cells (NPCs) from healthy donors, individuals with MGUS, or SMM patients (B, data set GSE5900; Zhan et al., 2007) and in plasma cells fromMGUS, MM,
and PCL patients (C, data set GSE2113; Mattioli et al., 2005). Increased BRD4 expression is observed in SMM (or MGUS) compared to NPCs (B) and in PCL
compared to MM (C) (nonparametric Kruskal-Wallis one-way analysis of variance; p < 0.001 and p = 0.0123, respectively; Dunn’s Multiple Comparison post-hoc
tests; p < 0.05 in both cases). For each box plot, the whiskers representminimumandmaximum values, the lower and upper boundaries denote the 25th and 75th
percentile, respectively, and the horizontal line represents the median value for each group.
(D) Copy number analysis of the BRD4 locus at human chromosome 19p13.1 in primary samples from 254 MM patients. Chromosome 19p amplifications are
common in MM. See also Figure S1.
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a rationale for the study of BET bromodomains, and BRD4 in
particular, as tumor dependencies in MM.
BET Inhibition with JQ1 Arrests c-Myc Transcriptional
Programs
To test the hypothesis that BET inhibition will specifically abro-
gate Myc-dependent transcription, we utilized global transcrip-
tional profiling and unbiased gene set enrichment analysis
(GSEA). We first characterized the transcriptional consequences
of BET inhibition in three MM cell lines with genetically distinct
activating lesions at the MYC locus (KMS11, MM.1S, and
OPM1) (Dib et al., 2008). Unsupervised hierarchical clustering
segregated samples based on treatment assignment, suggest-
ing a common transcriptional consequence in response to JQ1
(Figure 2A). Acute JQ1 treatment did not prompt global, nonspe-
cific transcriptional silencing but instead produced significant
changes in a finite number of genes (88 down- and 25 upregu-
lated genes by 2-fold or greater in all three MM lines).
To examine higher-order influences on biological networks
regulated by c-Myc, we evaluated four canonical transcriptional
signatures ofMYC-dependent genes (Kim et al., 2006; Schlosser
et al., 2005; Schuhmacher et al., 2001; Zeller et al., 2003). All four
signatures were strongly correlated with downregulation of ex-
pression by JQ1 (Figure 2B). As a measure of the specificity of
this effect, an open-ended enrichment analysis was performed
on the entire set of transcription factor target gene signatures
available from the Molecular Signatures Database (MSigDB).
Gene sets defined by adjacency to Myc-binding motifs were in
almost all cases significantly enriched in JQ1-suppressed genes
(Figures 2C and 2D). In marked contrast, JQ1 treatment did not
exert significant suppression of gene sets for other transcription
factors linked to pathophysiology of MM, including NF-kB, AP-1,
STAT3, GR, and XBP-1 (Figure 2E and Figure S2). Notably, 27 of
the 28 significantly correlated gene sets are annotated as pre-
dicted targets of MYC or E2F (Figure 2C and Figure S2). Consis-
tent with Myc-specific inhibition, biological modules associated
with Myc (e.g., ribosomal biogenesis and assembly and glycol-
ysis) were also anticorrelated with JQ1 treatment (Figure 2E).
BET bromodomain inhibition by JQ1 confers a selective repres-
sion of transcriptional networks induced by c-Myc.
Regulation ofMYC Transcription by BET Bromodomains
An unexpected finding was the observed, robust inhibition of
MYC expression following treatment with JQ1 (Figure 2A). As
MYC is commonly activated by upstream oncogenic signaling
pathways, we studied the consequence of JQ1 treatment on
the expression of 230 cancer-related genes in a human MM
cell line (MM.1S) using a multiplexed transcript detection assay(E) Expression levels of BRD4 (compared to BRDT) in human MM cell lines. Aste
(F) BRD4 expression (depicted on a linear scale for three different oligonucleot
absence of HS-5 bone marrow stromal cells.
(G) Silencing of BET bromodomains impairs proliferation in MM cells. Results of a
presented in rank order of ascending B scores. The effect of shRNAs targeting
annotated by gene. Gray dots represent results for non-BET bromodomain shRN
(H) Silencing of BET bromodomain family members in MM cells. Viability of INA-
reported as mean B scores (± SD of the two normalized replicates).(Figure 3A). Excellent concordance was observed between repli-
cate measurements of expressed genes (Figure S3A). Unsuper-
vised hierarchical clustering segregated replicate data correctly
into early- and late-treatment time points. Surprisingly, we ob-
served immediate, progressive, and profound downregulation
ofMYC transcription itself, a unique finding among all transcripts
studied (p < 0.05).
Downregulation of MYC was further confirmed by RT-PCR
and immunoblot (Figures 3B and 3C). This effect was BET bro-
modomain specific, supported by the nearly comparable activity
of an analogous BET inhibitor subsequently published by Glaxo
SmithKline (iBET) (Figure 1A) (Nicodeme et al., 2010) and the lack
of activity of the inactive (-)- JQ1 enantiomer, which we previ-
ously characterized as structurally incapable of inhibiting BET
bromodomains (Filippakopoulos et al., 2010) (Figure 3C). Inhibi-
tion of MYC transcription by JQ1 was observed to be dose and
time dependent, with peak inhibition at submicromolar concen-
trations (Figures 3D and 3E). Rapid depletion of chromatin-
bound c-Myc was confirmed by nuclear ELISA transcription
factor-binding assays (Figure 3F). In contrast, NF-kB and AP-1
chromatin-binding assays failed to reveal any decrease in DNA
binding within 8 hr of JQ1 treatment (Figure 3G and Figure S4A).
To assess the breadth of these findings in MM, we expanded
gene expression studies to threeMMcells with distinct lesions at
the MYC locus. MM.1S cells have a complex MYC rearrange-
ment involving an IgH insertion at the breakpoint of a derivative
chromosome der3t(3;8); KMS-11 cells have both MYC dupli-
cation and inversion; and OPM1 cells feature a der(8)t(1;8)
(Dib et al., 2008). Among 230 genes studied, MYC was one of
only four genes downregulated by treatment with JQ1, along
with MYB, TYRO3, and TERT (Figure 3H and Figure S4B).
Immunoblotting analyses confirmed the JQ1 suppression of
c-Myc protein expression in a further expanded panel of Myc-
dependent MM cell lines (Figure 3I). Despite the intriguing poten-
tial effect on E2F transcriptional function andMYB gene expres-
sion, JQ1 did not influence E2F or MYB protein abundance
through 24 hr of drug exposure (Figures S4C and S4D). Together,
these data support the general observation that BET inhibition
specifically suppresses MYC transcription across MM cells
with different genetic lesions affecting the MYC locus and with
striking selectivity in comparison to other oncogenic transcrip-
tions factors with established roles in MM pathophysiology.BRD4 Binds IgH Enhancers, RegulatingMYC Expression
and Function
Based on the integrated, functional genomic analysis of BET bro-
modomains in MM (Figure 1), we pursued further mechanistic
studies of BRD4. Silencing of BRD4 using directed shRNAsrisks denote cell lines with amplification of the BRD4 locus (19p13.1).
ide microarray probes) in INA-6 MM cells cultured in vitro in the presence or
n arrayed lentiviral screen using a diverse shRNA library in INA-6 MM cells are
BET bromodomains on INA-6 cell viability is highlighted by red circles and
As.
6 MM cells exposed to shRNAs directed against BRD2, BRD3, and BRD4 are
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Figure 2. Inhibition of Myc-Dependent Transcription by the JQ1 BET Bromodomain Inhibitor
(A) Heatmap representation of the top 50 down- and upregulated genes (p < 0.001) following JQ1 treatment in MM cell lines. Data are presented row normalized
(range from 3- to 3 standard deviations from median in expression). MYC (arrow) is downregulated by JQ1 treatment.
(B) GSEA of four Myc-dependent gene sets (Kim et al., 2006; Schlosser et al., 2005; Schuhmacher et al., 2001; Zeller et al., 2003) in transcriptional profiles of MM
cells treated (left) or untreated (right) with JQ1.
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validated by RT-PCR analysis (Figure 4A) elicited a marked
decrease in MYC transcription (Figure 4B) accompanied by G1
cell-cycle arrest in JQ1-sensitive MM cells (OPM-1) (Figure 4B
and Figure S5A). We reasoned that early and sustained JQ1-
induced suppression of MYC transcription may be mechanisti-
cally explained by physical interaction of BRD4 with regulatory
elements influencing MYC expression. Indeed, avid binding of
BRD4 to established IgH enhancers was observed by chromatin
immunoprecipitation (ChIP) in MM.1S cells (Figure 4C and Fig-
ure S6), which harbor an IgH insertion proximal to theMYC tran-
scriptional start site (TSS). BRD4 binding was not observed at
five characterized enhancer regions adjacent to the MYC gene
(Pomerantz et al., 2009a, 2009b). JQ1 treatment (500 nM) for
24 hr significantly depleted BRD4 binding to IgH enhancers
and the TSS, supporting direct regulation of MYC transcription
by BET bromodomains and a model whereby BRD4 acts as a
coactivator of MYC transcription potentially through long-range
interactions with distal enhancer elements. Forced overexpres-
sion of c-Myc in MM cells (OPM1) by retroviral infection rescues,
in part, the cell-cycle arrest observed with JQ1 treatment (Fig-
ures 4D and 4E), arguing that MYC downregulation by JQ1
contributes functionally to cell physiology in MM.
Therapeutic Implications of BET Inhibition in MM
Based on this mechanistic rationale, we evaluated the thera-
peutic opportunity ofMYC transcriptional inhibition using estab-
lished translational models of MM. Antiproliferative activity of
JQ1 was assessed using a panel of 25 MM cell lines or isogenic
derivative lines (Figure 5A). MM cell proliferation was uniformly
inhibited by JQ1 (Figure 5A), including several MM cell lines
selected for resistance to FDA-approved agents (dexametha-
sone-resistant MM.1R and melaphalan-resistant LR5). As ex-
pected, MM cells possessing diverse genetic lesions involving
MYC (Dib et al., 2008) were comparably sensitive to JQ1
(Figure 5B).
As interaction of MM cells with BMSCs is widely recognized to
confer resistance to numerous therapeutic agents (Hideshima
et al., 2007; McMillin et al., 2010), we sought to characterize
the effect of BMSCs on MM cell sensitivity to BET inhibition.
Using compartment-specific bioluminescence imaging assays
(CS-BLI), we observed that the sensitivity of MM cell lines to
JQ1 is largely unchanged by the presence of HS-5 bone marrow
stroma cells (Figure 5C). This pattern of broad activity in MM
without evident stroma-mediated chemoresistance has been
associated with efficacy of FDA-approved agents bortezomib
and lenalidomide.
MM cells were then further phenotyped for Myc-specific bio-
logical effects of BET inhibition. Flow cytometry of JQ1-treated
MM.1S cells revealed a pronounced decrease in the proportion
of cells in S phase, with a concomitant increase in cells arrested(C) Quantitative comparison of all transcription factor target gene sets available fr
Data are presented as scatterplot of false discovery rate (FDR) versus normalized e
sets for MYC (red), E2F (black), or other (gray) transcription factors.
(D) GSEA showing downregulation in JQ1-treated MM cells of a representative se
(E) Table of gene sets enriched among genes downregulated by JQ1 in MM cell
enrichment score (NES), and test of statistical significance (FDR q value). The bo
gene sets of MM master regulatory proteins, enriched among genes downregulain G0/G1 (Figure 6A). Only a modest induction of apoptosis was
observed after 48 hr of JQ1 treatment (Figure 6B), in contrast to
the nonselective cytotoxic kinase inhibitor staurosporine (Fig-
ure S5B). Transcripts previously associated with induction of
cellular senescence were enriched following treatment with
JQ1, by GSEA (Figure 6C). Experimentally, treatment with JQ1
resulted in pronounced cellular senescence by b-galactosidase
staining (Figure 6D). Overall, these phenotypes of arrested prolif-
eration, G1 cell-cycle arrest, and cellular senescence are highly
specific to anticipated effects of inhibiting cellular c-Myc func-
tion (Wu et al., 2007).
We next extended the study of JQ1 in MM cells to primary MM
samples. JQ1 exposure led to a significant reduction in cell
viability among the majority of CD138+ patient-derived MM
samples tested (Figure 7A). In primary cells isolated from
a patient with relapsed/refractory MM, JQ1 treatment ex vivo
conferred a time-dependent suppression of c-Myc expression
(Figure 7B). In contrast, JQ1 treatment of phytohemaglutinin
(PHA)-stimulated peripheral blood mononuclear cells (PBMCs)
suppressed PHA-induced proliferation but did not adversely
influence cell viability, indicating that the anti-MM effect of JQ1
is not accompanied by a nonspecific, toxic effect on all hemato-
poietic cells (Figure S7A).
To model the therapeutic effect of JQ1 in vivo, we evaluated
anti-MM efficacy in multiple orthotopic models of advanced
disease. First, JQ1 was studied using an established, biolumi-
nescent MMmodel (MM.1S-luc), which recapitulates the clinical
sequelae, anatomic distribution of MM lesions, and hallmark
bone pathophysiology observed in MM patients (Mitsiades
et al., 2004). Tumor-bearing mice were treated with JQ1 admin-
istered by intraperitoneal injection (50 mg/kg daily) or vehicle
control. JQ1 treatment significantly decreased the burden of
disease measured by serial, whole-body, noninvasive biolumi-
nescence imaging (Figures 7C and 7D). Importantly, treatment
with JQ1 resulted in a significant prolongation in overall survival
compared to vehicle-treated animals (Figure 7E). In a second
plasmacytoma xenograft that more accurately models ex-
tramedullary disease, JQ1 also exhibited a significant disease-
modifying response (Figure S7B). Finally, the effect of JQ1 was
explored in the genetically engineeredmodel ofMYC-dependent
MM (Chesi et al., 2008). To date, two Vk*MYC mice with estab-
lished disease and measurable M-protein have completed
14 days of JQ1 treatment (25 mg/kg daily, adjusted to tolera-
bility). Both animals reveal objective evidence of response as-
sessed by reduction of serum immunoglobulins, including a
complete response (CR) in the second animal (Figure 7F and Fig-
ure S7C). In this faithful orthotopic and nonproliferative model,
the only FDA-approved agents, bortezomib, melphalan and
cyclophosphamide, have previously prompted a CR (Chesi
et al., 2008). These results establish in vivo proof of conceptom the MSigDB by GSEA for reduced expression in JQ1-treated MM cell lines.
nrichment score (NES) for each evaluated gene set. Colored dots indicate gene
t of genes with proximal promoter regions containing Myc-Max-binding sites.
s (top group), highlighting the number of genes in each set (n), the normalized
ttom group represents comparisons of top-ranking transcription factor target
ted by JQ1 in MM cells. See also Figure S2.
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Figure 3. BET Inhibition Suppresses MYC Transcription in MM
(A) Heatmap of cancer-related genes expressed in MM cells (MM.1S), treated with JQ1 (500 nM over 1, 4, and 8 hr).MYC (red) is downregulated by JQ1 in a time-
dependent manner, uniquely among all oncogenes studied (230 total). MYC was identified as the only statistically significant decrease in transcription at all four
time points analyzed (p < 0.05). See also Figure S3.
(B) Quantitative RT-PCR analysis forMYC levels in JQ1-treated MM.1S cells (500 nM, 0–8 hr). Data are presented as ratio ofMYC expression at each time point
compared to baselineMYC expression (mean ± SD). Asterisks denote the level of statistical significance (*p < 0.01, **p < 0.0002, ***p < 0.006; paired Student’s t
test each relative to t = 0 hr).
(C) The active JQ1 enantiomer and the structurally analogous BET inhibitor iBET (Nicodeme et al., 2010), but not the inactive (-)-JQ1 enantiomer, downregulate
c-Myc expression, as determined by immunoblotting of MM.1S cells treated with compounds (500 nM) or vehicle control for 24 hr.
(D and E) Immunoblotting analyses of the (D) dose- and (E) time-dependent effects of JQ1 treatment on c-Myc expression in MM.1S cells.
(F and G) Selective depletion of nuclear c-Myc following JQ1 treatment (500 nM) as measured by ELISA-based DNA-binding assays for the activity of (F) c-Myc
(depleted after 1–2 hr) and (G) NF-kB family members (unaffected). Data represent mean ± SEM. See also Figure S4.
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for 5 days before analysis by qRT-PCR. Data normalized to GAPDH are presented as mean ± SEM of three biological replicates.
(B) Cell-cycle analysis of OPM1 cells transduced with the indicated shRNA for 6 days. BrdU staining (APC) identifies the fraction of cells in S phase. See also
Figure S5.
(C) ChIP studies of BRD4 (anti-BRD4; Bethyl) binding toMYC TSS or proximal enhancers in MM.1S cells. Competitive displacement of BRD4 from IgH enhancers
is observed upon treatment with JQ1 (500 nM for 24 hr, red bars) compared to vehicle control (black bars). Data represent mean ± SEM of three replicates.
See also Figure S6.
(D) Immunoblotting of whole-cell lysates from empty MSCV vector- or Myc overexpression vector-transduced OPM1 cells after treating with JQ1 (500 nM, 24 hr)
or DMSO control.
(E) Cell-cycle analysis of either empty or Myc-overexpressing OPM1 cells treated with JQ1 (500 nM, 24 hr). BrdU staining (APC) identifies the fraction of cells
in S phase.for the investigational study of BET bromodomain inhibitors in
the treatment of MM.
DISCUSSION
Despite the centrality of Myc in the pathogenesis of cancer,
conventional approaches toward direct Myc inhibition have not(H) Heatmap of clustered gene expression data from multiplexed measurement
with JQ1 or vehicle control. Among 230 genes studied (Figure S4), four genes
downregulation. Replicate expression measurements exhibited high concordanc
(I) Immunoblotting study of four MM lines (KMS11, LR5, OPM1, and INA-6) identproven successful. To date, efforts to target c-Myc have identi-
fied only a small number of molecules with low biochemical
potency and limited biological characterization (Bidwell et al.,
2009; Hammoudeh et al., 2009; Jeong et al., 2010), underscoring
both the challenge of targeting c-Myc as well as the enduring
need for chemical probes of c-Myc transcriptional function.
Considering chromatin as a platform for signal transduction(Nanostring) of cancer-associated genes in three human MM cell lines treated
(MYC, TERT, TYRO3, and MYB) exhibited statistically significant (p < 0.05)
e among low and highly expressed genes (Figure S3B).
ifies a JQ1-induced decrease in c-Myc expression (500 nM, 24 hr).
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Figure 5. Antimyeloma Activity of JQ1 In Vitro
(A) A panel of MM cell lines was tested for in vitro sensitivity to JQ1 (12.5–800 nM, 72 hr) by measurement of ATP levels (Cell TiterGlo; Promega).
(B) MYC genomic status of selected MM cell lines from (A), as annotated (Dib et al., 2008).
(C) Activity of JQ1 against MM cell lines cultured in the presence (red lines) or absence (black lines) of the HS-5 stromal cell line, assessed by CS-BLI (McMillin
et al., 2010). Data represent mean ± SD for four biological replicates.(Schreiber and Bernstein, 2002), we have undertaken to inhibit
Myc transcription and function through displacement of chro-
matin-bound, coactivator proteins using competitive small mole-
cules. Using a first-in-class, small-molecule bromodomain in-
hibitor developed by our laboratories, JQ1, we validate BET
bromodomains as determinants of c-Myc transcription and as
therapeutic targets in MM, an ideal model system for the mech-
anistic and translational study of Myc pathway inhibitors.
Most importantly, we illustrate the feasibility of selectively
downregulating transcription of MYC itself via the molecular
action of a selective, small molecule. The ensuing suppression
of c-Myc protein levels, depletion of chromatin-bound c-Myc,912 Cell 146, 904–917, September 16, 2011 ª2011 Elsevier Inc.and concomitant downregulation of the Myc-dependent tran-
scriptional network lead to growth-inhibitory effects sharing the
specificity of phenotypes associated with prior genetic models
ofMyc inhibition. These are notable observations that distinguish
the transcriptional consequences of BET inhibition from other
nonselective transcriptional inhibitors, such as actinomycin D,
a-amanitin, and flavopiridol.
A compelling finding is the observed, direct interaction of
BRD4with IgH enhancers inMMcells possessing IgH rearrange-
ment into the MYC locus and the depletion of BRD4 binding by
JQ1. This suggests BET inhibition as a strategy for targeting
other structural rearrangements in cancer involving IgH or other
ADC
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Figure 6. JQ1 Induces Cell-Cycle Arrest and Cellular Senescence in MM Cells
(A and B) Flow cytometric evaluation of propidium iodide (PI) staining for cell-cycle analysis (A) and detection of Annexin V-positive apoptotic cells (B) in
JQ1-treated MM.1S cells (0–48 hr, 500 nM).
(C) Enrichment of senescence-associated genes among JQ1-suppressed genes in MM.1S cells.
(D) Induction of cellular senescence in JQ1-treated MM.1S cells (500 nM, 48 hr), as detected by b-galactosidase staining.strong enhancers and has potential implications for the modu-
lation of immunoglobulin gene expression in autoimmune
diseases.
An unexpected finding was the pronounced and concordant
suppression of multiple E2F-dependent transcriptional signa-
tures. In this instance, E2F1 protein and transcript levels were
not affected byBET inhibition, suggesting either an unrecognized
function of BET bromodomains in E2F transcriptional complexes
or a dominant effect of Myc downregulation causing cell-cycle
arrest in G1 leading to silencing of E2F. These observations are
also compatible with the known role of Myc and E2F1 as tran-
scriptional collaborators in cell-cycle progression and tumor
cell survival (Matsumura et al., 2003; Trimarchi and Lees, 2002).
Insights provided by our study identify rational strategies for
combination therapeutic approaches warranting exploration inMM. MYC activation is commonly accompanied by antiapop-
totic signaling in human cancer. In MM, constitutive or microen-
vironment-inducible activation of antiapoptotic Bcl-2 proteins
has been reported (Harada et al., 1998; Legartova et al., 2009).
Thus, Myc pathway inhibition by JQ1 may demonstrate syner-
gism with targeted proapoptotic agents (e.g., ABT-737) (Olters-
dorf et al., 2005; Trudel et al., 2007). Additionally, the selective
effect of JQ1 on Myc and E2F1 transcriptional programs pro-
vides an opportunity to combine BET inhibitors with pathway-
directed antagonists of the NF-kB, STAT3, XBP1, or HSF1 tran-
scriptional programs.
Direct inhibition of c-Myc remains a central challenge in the
discipline of ligand discovery. Inhibition of MYC expression and
function, demonstrated herein, presents an immediate opportu-
nity to study and translate the concept of c-Myc inhibition moreCell 146, 904–917, September 16, 2011 ª2011 Elsevier Inc. 913
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Figure 7. Translational Implications of BET Bromodomain Inhibition in MM
(A) JQ1 arrests the proliferation of primary, patient-derived CD138+ MM cells (Cell TiterGlo; Promega). Data represent the mean ± SD of four replicates per
condition.
(B) c-Myc immunoblot shows JQ1-induced downregulation in short-term culture of primary, patient-derived MM cells (500 nM, duration as indicated).
(C) Representative whole-body bioluminescence images of SCID-beige mice orthotopically xenografted after intravenous injection with MM.1S-luc+ cells and
treated with JQ1 (50 mg/kg IP daily) or vehicle control.
(D) Tumor burden of SCID-beige mice orthotopically xenografted after intravenous injection with MM.1S-luc+ cells. Upon detection of MM lesions diffusely
engrafted in the skeleton, mice were randomly assigned to receive JQ1 (50 mg/kg IP daily) or vehicle control. Data are presented as mean ± SEM (n = 10/group).
(E) Survival curves (Kaplan-Meier) of mice with orthotopic diffuse MM lesions show prolongation of overall survival with JQ1 treatment compared to vehicle
control (log-rank test, p < 0.0001).
(F) Serumprotein electrophoresis to detect monoclonal, tumor-derived immunoglobulin (M-protein) in twoMM-bearing Vk*mycmice before or after 7 and 14 days
of JQ1 treatment. JQ1 treatment induced partial and complete responses, respectively, in mouse 1 and mouse 2.
See also Figure S7.broadly in human cancer. During the course of this research,
a collaborative effort with the laboratories of Christopher Vakoc
and Scott Lowe revealed BRD4 as a tumor dependency in acute
myeloid leukemia. Consistent with our observations described
here in MM, leukemia cells similarly require BRD4 to sustain914 Cell 146, 904–917, September 16, 2011 ª2011 Elsevier Inc.MYC expression to enforce aberrant self-renewal (Zuber et al.,
2011). Collectively, these findings highlight a broad role for
BRD4 in maintaining MYC expression in diverse hematopoietic
malignancies and suggest the utility of drug-like BET bromodo-
main inhibitors as therapeutic agents in these diseases.
EXPERIMENTAL PROCEDURES
Gene Expression Analysis
MM cells treated with JQ1 (500 nM, 24 h) were processed for transcriptional
profiling using Affymetrix Human Gene 1.0 ST microarrays. Expression of indi-
vidual genes was assessed in the context of dose- and time-ranging experi-
ments by real-time quantitative polymerase chain reaction, multiplexed direct
detection (Nanostring), and immunoblotting using antibodies as described in
the Extended Experimental Procedures.
Chromatin Immunoprecipitation
ChIP was performed on MM.1S cells cultured in the presence or absence of
JQ1 (500 nM, 24 hr). Specific antibodies, detailed methods, and primer se-
quences for MYC and IgH enhancers, as well as the MYC TSS, are described
in the Extended Experimental Procedures.
In Vitro and In Vivo MM Studies
The impact of JQ1 on cell viability, proliferation, and cell cycle was assessed in
human MM cells as documented in the Extended Experimental Procedures.
In vivo efficacy studies were performed with protocols approved by Institu-
tional Animal Care and Use Committees at the DFCI or Mayo Clinic Arizona.
JQ1 was administered by intraperitoneal injection into SCID-beige mice with
MM lesions established after subcutaneous or intravenous injections and in
nonimmunocompromised tumor-bearing Vk*mycmice. Tumor burden in these
models was quantified by caliper measurement, whole-body bioluminescence
imaging, and serum protein electrophoresis, respectively, as detailed in the
Extended Experimental Procedures.ACCESSION NUMBERS
Oligonucleotide microarray data have been deposited in the Gene Expression
Omnibus under the accession number GSE31365.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures,
seven figures, and one table and can be found with this article online at
doi:10.1016/j.cell.2011.08.017.
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